Monitoring occupational exposure to cancer chemotherapy drugs

被引:60
作者
Baker, ES
Connor, TH
机构
[1] UNIV TEXAS, HLTH SCI CTR, SCH PUBL HLTH, HOUSTON, TX 77225 USA
[2] NASA, HOUSTON, TX USA
关键词
antineoplastic agents; compliance; guidelines; health professions; metabolism; methodology; safety; tests; laboratory; toxicity; environmental; urine levels;
D O I
10.1093/ajhp/53.22.2713
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Reports of the health effects of handling cytotoxic drugs and compliance with guidelines for handling these agents are briefly reviewed, and studies using analytical and biological methods of detecting exposure are evaluated. There is little conclusive evidence of detrimental health effects from occupational exposure to cytotoxic drugs. Work practices have improved since the issuance of guidelines for handling these drugs, but compliance with the recommended practices is still inadequate. Of 64 reports published since 1979 on studies of workers' exposure to these drugs, 53 involved studies of changes in cellular or molecular endpoints (biological markers) and 12 described chemical analyses of drugs or their metabolites in urine (2 involved both, and 2 reported the same study). The primary biological markers used were urine mutagenicity, sister chromatid exchange, and chromosomal aberrations; other studies involved formation of micronuclei and measurements of urinary thioethers. The studies had small sample sizes, and the methods were qualitative, nonspecific, subject to many confounders, and possibly not sensitive enough to detect most occupational exposures. Since none of the currently available biological and analytical methods is sufficiently reliable or reproducible for routine monitoring of exposure in the workplace, further studies using these methods are not recommended; efforts should focus instead on widespread implementation of improved practices for handling cytotoxic drugs.
引用
收藏
页码:2713 / 2723
页数:11
相关论文
共 147 条
[41]  
FORNI A, 1984, IARC SCI PUBL, V59, P325
[42]   LIMITATIONS OF THE SALMONELLA MAMMALIAN MICROSOME ASSAY (AMES TEST) TO DETERMINE OCCUPATIONAL EXPOSURE TO CYTOSTATIC DRUGS [J].
FRIEDERICH, U ;
MOLKO, F ;
HOFMANN, V ;
SCOSSA, D ;
HANN, D ;
WURGLER, FE ;
SENN, HJ .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1986, 22 (05) :567-575
[43]   DNA-DAMAGE IN NURSES HANDLING ANTINEOPLASTIC AGENTS [J].
FUCHS, J ;
HENGSTLER, JG ;
JUNG, D ;
HILTL, G ;
KONIETZKO, J ;
OESCH, F .
MUTATION RESEARCH-GENETIC TOXICOLOGY, 1995, 342 (1-2) :17-23
[44]   UNDIFFERENTIATED NASOPHARYNGEAL-TYPE CARCINOMA IN A NURSE HANDLING CYTOSTATIC AGENTS [J].
GABRIELE, P ;
AIROLDI, M ;
SUCCO, G ;
BRANDO, V ;
REDDA, MGR .
ORAL ONCOLOGY-EUROPEAN JOURNAL OF CANCER PART B, 1993, 29B (02) :153-153
[45]  
GIBSON JF, 1984, LANCET, V1, P100
[46]   URINARY MUTAGENICITY ASSAYS - A PROBLEM ARISING FROM THE PRESENCE OF HISTIDINE ASSOCIATED GROWTH-FACTORS IN XAD-2 PREPARED URINE CONCENTRATES, WITH PARTICULAR RELEVANCE TO ASSAYS CARRIED OUT USING THE BACTERIAL FLUCTUATION TEST [J].
GIBSON, JF ;
BAXTER, PJ ;
HEDWORTHWHITTY, RB ;
GOMPERTZ, D .
CARCINOGENESIS, 1983, 4 (11) :1471-1476
[47]   SISTER CHROMATID EXCHANGES AND CHROMOSOME-ABERRATIONS IN LYMPHOCYTES OF NURSES HANDLING ANTINEOPLASTIC DRUGS [J].
GOLONIBERTOLLO, EM ;
TAJARA, EH ;
MANZATO, AJ ;
VARELLAGARCIA, M .
INTERNATIONAL JOURNAL OF CANCER, 1992, 50 (03) :341-344
[48]   HANDLING ANTINEOPLASTIC-DRUG ADMIXTURES AT CANCER CENTERS - PRACTICES AND PHARMACIST ATTITUDES [J].
GREGOIRE, RE ;
SEGAL, R ;
HALE, KM .
AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1987, 44 (05) :1090-1095
[49]  
GRIESEMER RA, 1985, IARC SCI PUBL, V83, P409
[50]  
Gullo S M, 1988, Oncol Nurs Forum, V15, P595